Clinical trials: Nervous System Disorders
Obstructive Sleep Apnea, OSA
Dimethyl Fumarate for Obstructive Sleep Apnea
The overall purpose of this study is to determine whether the oral medication dimethyl fumarate is an effective treatment for obstructive sleep apnea in patients who are unable, unwilling, or uneager to use positive airway…
- Conditions
- Obstructive Sleep Apnea, OSA, Sleep Apnea
- Trial name
- NCT02438137
- Testing
- Dimethyl fumarate
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Michigan
Chemotherapeutic Agent Toxicity, Neuropathy
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary…
- Conditions
- Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain
- Trial name
- NCT02311907
- Testing
- Carboplatin, Glutathione, Laboratory Biomarker Analysis
- Where
- 390 sites in United States
- Volunteers
- 195 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pituitary Tumors
Barrow Nasal Inventory Survey
The purpose of this study is to evaluate patient nasal outcome following endo-nasal surgery. This type of surgery is conducted for pituitary and skull base tumors.
- Trial name
- BNI (NCT01322945)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Epilepsy
A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Single centre, double-blind, randomised, placebo-controlled study of two dosage regimens of BIA 2-093 - 1800 mg (Group 1) and 2400 mg (Group 2) - in two groups of healthy male volunteers
- Trial name
- NCT01879345
- Testing
- BIA 2-093 - 1800 mg (Group 1), BIA 2-093 - 2400 mg (Group 2)
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Synkinesis
Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis
This proposal will prospectively assess the social, physical, and emotional recognition function in participants with synkinesis.
- Trial name
- NCT04148872
- Testing
- Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Opioid Use, Pain
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain…
- Conditions
- Opioid Use, Pain, Marijuana Use
- Trial name
- NCT04827992
- Testing
- Cannabis, Prescription Opioid Taper Support (POTS)
- Where
- 3 sites in United States
- Volunteers
- 87 people
- Sponsor
- Massachusetts General Hospital
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site…
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Trial name
- NCT02360215
- Testing
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Where
- 220 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- NRG Oncology
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices
Epilepsy
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic…
- Trial name
- NCT00334958
- Testing
- Rufinamide
- Where
- 77 sites in United States
- Volunteers
- 356 people
- Sponsor
- Eisai Inc.
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Medication Overuse Headache
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
- Trial name
- NCT02583425
- Testing
- DFN-11 Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Covid19, Muscle Atrophy
Electrical Stimulation for Critically Ill Covid-19 Patients
Unfortunately, hospital-acquired weakness is highly prevalent among COVID-19 hospitalized patients, who often require prolonged bed-rest or paralytics for an extended period of time in order to maintain oxygenation.
- Conditions
- Covid19, Muscle Atrophy, Muscle Weakness
- Trial name
- Phase I (NCT04685213)
- Testing
- Electrical Stimulation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Baylor College of Medicine
Alcohol Drinking, Binge Drinking
Alcohol, Behavior, and Brain Imaging
To evaluate the relationship of extraversion to both the acute subjective and behavioral effects of alcohol, and the neural reactivity to the anticipation of reward.
- Conditions
- Alcohol Drinking, Binge Drinking, Drinking Behavior, Substance-Related Disorders
- Trial name
- (DARC) (NCT03930446)
- Testing
- Ethanol
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Sudden Deafness
Sudden Deafness Treatment Trial
This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing loss (inner ear hearing loss affecting one ear…
- Trial name
- SSNHL (NCT00097448)
- Testing
- prednisone, methylprednisolone sodium succinate
- Where
- 14 sites in United States
- Volunteers
- 255 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals
Hearing Loss
Innovations in Clinical Care of CE Approved Nucleus Cochlear Implant Recipients
This study is to evaluate new approaches to device fitting and diagnostics for cochlear implant users. The evaluation can be performed in the laboratory in an acute session or in real world environments with take-home device use…
- Trial name
- NCT05270876
- Testing
- Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique
- Where
- 5 sites in Australia, Belgium
- Volunteers
- 20 people
- Sponsor
- Cochlear
Migraine
Ictal and Interictal Inflammatory Markers in Migraine
The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches.
- Trial name
- NCT01138150
- Testing
- Treximet
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Johns Hopkins University
Cerebral Aneurysm
DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial
Endovascular treatment with platinum coils is safe and effective in preventing rebleeding of intracranial aneurysms. Unfortunately, endovascular treatment of aneurysms with coils has been associated with incomplete occlusion at…
- Trial name
- DELTA (NCT01943591)
- Testing
- Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils
- Where
- 15 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Meniere Disease
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- NCT03664674
- Testing
- OTO-104
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 148 people
- Sponsor
- Otonomy, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.